Phaseline

Targets › DCXR

DCXR (L-xylulose reductase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Aug 2029.

Catalyzes the NADPH-dependent reduction of several pentoses, tetroses, trioses, alpha-dicarbonyl compounds and L-xylulose. Can use both NAD and NADP as cosubstrate but shows higher activity with NADP. Participates in the uronate cycle of glucose metabolism. (UniProt, Q7Z4W1)

Open in Phaseline: the race on DCXR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PharmaMarLurbinectedin
Alkylating agent that binds to DNA and causes strand breaks
DCXRPhase 3LeiomyosarcomaAug 2029

Conditions

Leiomyosarcoma (1)

Modalities

small molecule (1)

Companies

PharmaMar (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.